Stephen G Worthley
Overview
Explore the profile of Stephen G Worthley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
2558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreno R, Kandzari D, Kirtane A, Windecker S, Latib A, Kedhi E, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(6):100432.
PMID: 39132364
Background: Small reference vessel diameters (RVDs) are a predictor of ischemic events after coronary stenting. Among patients at high bleeding risk (HBR) precluding long-term dual antiplatelet therapy (DAPT), those with...
2.
Sultan I, Reardon M, Sondergaard L, Chehab B, Smith D, Walton A, et al.
Struct Heart
. 2024 Aug;
8(4):100293.
PMID: 39100579
Background: The Navitor Investigational Device Exemption (IDE) study is a prospective, multicenter, global study assessing the safety and effectiveness of the Navitor valve in a population with severe, symptomatic aortic...
3.
Reardon M, Chehab B, Smith D, Walton A, Worthley S, Manoharan G, et al.
JACC Cardiovasc Interv
. 2023 Mar;
16(6):681-689.
PMID: 36990558
Background: The self-expanding, intra-annular Navitor (Abbott Structural Heart) valve includes an outer cuff to reduce paravalvular leak (PVL) and large stent cells for future coronary access. Objectives: The purpose of...
4.
Sondergaard L, Walton A, Worthley S, Smith D, Chehab B, Manoharan G, et al.
EuroIntervention
. 2023 Mar;
19(3):248-255.
PMID: 36895190
Background: The Navitor transcatheter heart valve (THV) is a self-expanding valve, with an intra-annular leaflet position and an outer cuff intended to reduce paravalvular leak (PVL). Aims: The aim of...
5.
Eccleston D, Duong M, Chowdhury E, Schwarz N, Reid C, Liew D, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836219
Background: Readmissions within 1 year after percutaneous coronary intervention (PCI) are common (18.6-50.4% in international series) and a burden to patients and health services, however their long-term implications are not...
6.
Eccleston D, Chowdhury E, Rafter T, Sage P, Whelan A, Reid C, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36615080
Several large registries have evaluated outcomes after percutaneous coronary intervention (PCI) in the USA, however there are no contemporary data regarding long-term outcomes after PCI, particularly comparing new generation drug-eluting...
7.
Camuglia A, Cole C, Boyne N, Hayman S, Cox S, Moore P, et al.
Heart Lung Circ
. 2022 Nov;
32(2):224-231.
PMID: 36344392
Background: Transcatheter aortic valve implantation (TAVI) is an established therapy for the treatment of aortic valve disease in appropriately selected patients. Previous studies using the self-expanding Portico transcatheter heart valve...
8.
Windecker S, Latib A, Kedhi E, Kirtane A, Kandzari D, Mehran R, et al.
JACC Cardiovasc Interv
. 2022 Jun;
15(11):1153-1163.
PMID: 35680195
Background: Resolute Onyx polymer-based zotarolimus-eluting stents (ZES) were noninferior in safety and effectiveness to BioFreedom polymer-free biolimus A9-coated stents (DCS) in high-bleeding-risk (HBR) patients treated with 1-month dual antiplatelet therapy...
9.
Kandzari D, Kirtane A, Mehran R, Price M, Simon D, Latib A, et al.
Catheter Cardiovasc Interv
. 2021 Sep;
99(3):583-592.
PMID: 34478233
Objectives: To compare clinical outcomes in high bleeding risk (HBR) patients with and without complex percutaneous coronary intervention (PCI) treated with Resolute Onyx zotarolimus-eluting stents (ZES) after 1-month dual antiplatelet...
10.
Kandzari D, Kirtane A, Windecker S, Latib A, Kedhi E, Mehran R, et al.
Circ Cardiovasc Interv
. 2020 Nov;
13(11):e009565.
PMID: 33167705
Background: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study...